NCT03772314View on ClinicalTrials.gov

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Idiopathic HypersomniaNarcolepsy Without Cataplexy
Interventions
DRUG

Modafinil

Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.

DRUG

Amphetamine-Dextroamphetamine

Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.

Trial Locations (1)

30329

Emory Sleep Center, Atlanta

All Listed Sponsors
collaborator

American Academy of Sleep Medicine

OTHER

lead

Emory University

OTHER

NCT03772314 - Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia | Biotech Hunter | Biotech Hunter